4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000075
SVP, GEN COUNSEL & CORP SEC sold 5,500 shares at an average $114.24 ($628,295)
- SVP, GEN COUNSEL & CORP SEC acquired 5,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-10-01 | Option exercise 10b5-1 | +5,500 | $21.41 | $117,755 | 34,123 | D |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-10-01 | Sale 10b5-1 | −1,414 | $113.38 | $160,321 | 32,709 | D |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-10-01 | Sale 10b5-1 | −3,056 | $114.37 | $349,512 | 29,653 | D |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-10-01 | Sale 10b5-1 | −1,030 | $115.01 | $118,462 | 28,623 | D |
| Derivatives | |||||||
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2024-10-01 | Option exercise · Stock Option (right to buy) 10b5-1 | −5,500 | 174,497 | D | ||
| Open-market sales · 5,500 sh · avg $114.24 · $628,295 | |||||||
Loading xslF345X05/wk-form4_1727986533.xml…